Risk of second primary malignancies among patients with carcinoid of the lung
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
The International Lung Cancer Consortium (ILCCO) is an international group of lung cancer researchers, established in 2004 with the aim of sharing comparable data from ongoing lung cancer case-control and cohort studies. Questionnaire data from a total of 26000 case-control pairs, and the biological samples from the majority of the subjects would be available. These studies are from different geographical areas and ethnicities. The overall objectives are to achieve greater power, especially for subgroup analyses, reduce duplication of research effort, replicate novel findings, and afford substantial cost savings through large collaborative efforts.
ETOP comprises 30 of the leading European Thoracic Oncology clinical and translational research groups and associations.
The European Thoracic Oncology Platform (ETOP) is a foundation with the purpose to promote exchange and research in the field of thoracic malignancies in Europe. It is a non-profit organisation with its legal seat in Bern, Switzerland.
The specific aims of ETOP are as follows:
- To serve as a meeting platform for European study groups and institutions dealing with thoracic malignancies
- To foster intergroup studies among, but not exclusively, European study groups and institutions
- To sponsor and/or perform own studies
- To foster scientific exchange on laboratory and clinical issues among interested parties and beyond
- To provide knowledge to partners in the field
British Thoracic Oncology Group (BTOG) was established in 2002 and aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and to facilitate and nurture clinical trial ideas into full protocols. BTOG represents all the disciplines involved in the care of lung cancer and mesothelioma throughout the UK. All individuals involved in any aspect of lung cancer or mesothelioma research, care or treatment are eligible to become members of BTOG. BTOG's annual conference is held in January every year.
2019 Impact Factor: 4.702
View More on Journal Insights
© 2019 Journal Citation Report
® Clarivate Analytics, 2020
About Lung Cancer
Original research articles, early reports, review articles, commentaries and editorials covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are all welcome. Letters to the journals are also welcomed although authors should be aware that the majority will be published online only. Early reports should briefly describe the initial results of a research topic and will be expedited through peer-review.
Manuscripts describing studies on cell lines will only be considered if the data compares at least two types of distinct cell lines and the results have general implications on the understanding of the biology of chest tumours. Authors of studies on cell lines must also agree to make freely available to other researchers any of the cells, clones of cells, or DNA or antibodies, etc, that were used in the research reported and that are not available from commercial suppliers.
Manuscripts should be submitted online at http://ees.elsevier.com/lungcancer and the instructions on this site should be closely followed.
These journal metrics provide authors with extra insight into the journals and help them in their journal selection process when submitting an article for publication.